Cargando…
Evaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome
OBJECTIVES: To evaluate whether three daily doses of GnRH agonist (Inj. Lupride 1 mg SC) administered 6 days after oocyte retrieval increases ongoing pregnancy rates following embryo transfer (ET) in cycles stimulated with the long GnRH agonist protocol. SETTINGS AND DESIGN: Prospective randomized c...
Autores principales: | Inamdar, Dattaprasad B, Majumdar, Abha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604836/ https://www.ncbi.nlm.nih.gov/pubmed/23532169 http://dx.doi.org/10.4103/0974-1208.106341 |
Ejemplares similares
-
The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS
por: Eftekhar, Maryam, et al.
Publicado: (2016) -
Gonadotropin-releasing hormone agonist for ovulation trigger – OHSS prevention and use of modified luteal phase support for fresh embryo transfer
por: Castillo, Juan Carlos, et al.
Publicado: (2020) -
Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients
por: Martazanova, Bella, et al.
Publicado: (2022) -
Effects of multiple doses of gonadotropin-releasing hormone agonist on the luteal-phase support in assisted reproductive cycles: A clinical trial study
por: Eftekhar, Maryam, et al.
Publicado: (2021) -
Luteal Support with very Low Daily Dose of Human Chorionic Gonadotropin after Fresh Embryo Transfer as an Alternative to Cycle Segmentation for High Responders Patients Undergoing Gonadotropin-Releasing Hormone Agonist-Triggered IVF
por: Carosso, Andrea Roberto, et al.
Publicado: (2021)